Oleracone F Alleviates Cognitive Impairment and Neuropathology in APPswe/PSEN1dE9 Mice by Reducing the Expression of Vascular Cell Adhesion Molecule and Leukocyte Adhesion to Brain Vascular Endothelial Cells
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032056 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Young-Sun Kwon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nanobiomedical Science & BK21 Four NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Republic of…. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, National Research Foundation of Korea government.
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most common neurodegenerative disease and the blood–brain barrier dysfunction has been suggested as a key pathological feature of the disease. Our research group successfully established a synthetic protocol for oleracones, a novel series of flavonoids isolated from the plant extract of Portulaca oleracea L. (PO). PO extract was reported to have anti-inflammatory and antioxidant effects, enhancing cognitive function. Thus, we investigated the effects and mechanism of oleracones on cognition using AD model transgenic mice (Tg; APPswe/PSEN1dE9). Oleracone F treatment significantly improved memory dysfunction in Tg mice. Oleracone F decreased the number, burden, and immunoreactivity of amyloid plaques and amyloid precursor protein (APP) protein levels in the brains of Tg mice compared to wild-type mice. Oleracone F also alleviated inflammation observed in Tg mice brains. In vitro studies in human microvascular endothelial cells (HBMVECs) demonstrated that oleracones D, E, and F blocked the elevations in VCAM-1 protein induced by tumor necrosis factor-α (TNF-α), hindering leukocyte adhesion to HBMVECs. Taken together, our results suggest that oleracones ameliorated cognitive impairment by blocking TNF-α-induced increases in VCAM-1, thereby reducing leukocyte infiltration to the brain and modulating brain inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nanobiomedical Science & BK21 Four NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Republic of Korea.
- Department of Convergence Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University, Seoul 07985, Republic of Korea.
- Department of Pharmacy, College of Pharmacy, Dankook University, Cheonan 31116, Republic of Korea.
ORCID-Profile: Se-Young Oh
Förderung
- National Research Foundation of Korea
- National Research Foundation of Korea government
Zitieren
APA
Kwon, Y. S., Ko, J. S., Oh, S. Y., Han, Y. T., & Jo, S. A. (2023). Oleracone F Alleviates Cognitive Impairment and Neuropathology in APPswe/PSEN1dE9 Mice by Reducing the Expression of Vascular Cell Adhesion Molecule and Leukocyte Adhesion to Brain Vascular Endothelial Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032056
Vancouver
Kwon YS, Ko JS, Oh SY, Han YT, Jo SA. Oleracone F Alleviates Cognitive Impairment and Neuropathology in APPswe/PSEN1dE9 Mice by Reducing the Expression of Vascular Cell Adhesion Molecule and Leukocyte Adhesion to Brain Vascular Endothelial Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032056
BibTeX
@article{Kwon2023,
author = {Kwon, Young-Sun and Ko, Jin-Sung and Oh, Se-Young and Han, Young Taek and Jo, Sangmee Ahn},
title = {Oleracone F Alleviates Cognitive Impairment and Neuropathology in APPswe/PSEN1dE9 Mice by Reducing the Expression of Vascular Cell Adhesion Molecule and Leukocyte Adhesion to Brain Vascular Endothelial Cells},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032056}
}
EUVIMED